Developer docs
API playgroundTry for free, no card

Search company profiles

Replimune Group

Full company profile

uuid0000pvi

Namestring
Replimune Group
Legal namestring
Replimune Group Inc.
Websiteurl
replimune.com
Company typeenum
Public
Founded yearint
2015
Descriptiontext

Replimune Group Inc. is a clinical-stage biotechnology company founded in 2015 and headquartered in Woburn, Massachusetts. The company develops a portfolio of oncolytic immunotherapies built on its proprietary RPx platform, which uses engineered herpes simplex virus type 1 (HSV-1) — incorporating transgenes such as GM-CSF, GALV-GP R-, and (for RP2) anti-CTLA-4 — to directly lyse tumor cells while inducing a systemic anti-tumor immune response capable of addressing heterogeneity that contributes to checkpoint inhibitor resistance. Its lead candidate, RP1 (vusolimogene oderparepvec), is being evaluated in combination with Bristol Myers Squibb's nivolumab for advanced melanoma; RP2 is in development for metastatic uveal melanoma and hepatocellular carcinoma (the latter in combination with Roche's atezolizumab/bevacizumab). Replimune retains full commercial rights to both assets.

The company operates an integrated model that includes a 63,000-square-foot GMP viral immunotherapy manufacturing facility in Framingham, Massachusetts, and a UK subsidiary (Replimune Ltd.) in Milton Park, Abingdon. Replimune is publicly traded on NASDAQ under the ticker REPL and has financed operations through venture rounds ($30M Series A in 2015, $55M Series B in 2017), later-stage private and public equity (~$655M across 2019-2024 including a $225M public offering in December 2022 and a $100M PIPE in June 2024), and a $200M structured debt facility from Hercules Capital (October 2022). Its intended revenue model is direct sales to oncology centers and specialty pharmacy distribution for RP1 and follow-on products, contingent on regulatory approval.

The commercial pathway has been materially disrupted: the FDA issued two Complete Response Letters rejecting RP1 in advanced melanoma, the second of which triggered a 60% workforce reduction in April 2026 and a signaled potential scale-back of U.S. manufacturing. As of December 31, 2025, Replimune held $269.1M in cash (approximately $325M pro forma following a January 2026 ATM raise and additional Hercules draw), and the FDA accepted the BLA resubmission with a PDUFA target action date of April 10, 2026 — the single most important catalyst for the company's forward trajectory.

Short descriptiontext

Replimune Group is a clinical-stage biotech developing engineered HSV-1 oncolytic immunotherapies (RP1, RP2, RPx platform) for advanced melanoma and other solid tumors, with lead candidate RP1 currently under FDA BLA review (PDUFA April 10, 2026).

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersWoburn, United States
HQ citystring
Woburn
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oncolytic immunotherapy, cancer immunotherapy, HSV-1 biologic platform, solid tumor treatment, checkpoint inhibitor combination
Industry1 code
PRIMARYHLAAACAF
Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Oncology Biologics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical/Biologic Product Sales
TypeOne Time License
Description

Pre-commercial stage company with no approved products. Expected to generate revenue from sales of RP1 and other oncolytic immunotherapy candidates pending FDA approval. Clinical-stage biotech developing oncolytic immunotherapies for solid tumors.

biospace.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Replimune is a clinical-stage biotechnology company developing a portfolio of investigational oncolytic immunotherapies built on its proprietary RPx platform, an engineered herpes simplex virus type 1 (HSV-1)-based technology designed to directly destroy tumor cells and activate a systemic anti-tumor immune response. Its lead candidates, RP1 (vusolimogene oderparepvec) and RP2, are being evaluated in combination with checkpoint inhibitors (nivolumab, atezolizumab, bevacizumab) for advanced melanoma, non-melanoma skin cancers, metastatic uveal melanoma, and hepatocellular carcinoma.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 33.6% objective response rate in advanced melanoma patients who failed anti-PD-1 therapy (IGNYTE trial)
+4 more records
Product overview1 text field

Replimune Group is a clinical-stage biotech company developing a portfolio of oncolytic immunotherapies built on its proprietary RPx platform. The company's core products include RP1 (vusolimogene oderparepvec) and RP2, both engineered herpes simplex virus type 1 (HSV-1)-based oncolytic immunotherapies designed to destroy tumors locally and ignite a systemic anti-tumor immune response. RP1 is being evaluated for advanced melanoma and non-melanoma skin cancers, while RP2 is being studied for metastatic uveal melanoma and hepatocellular carcinoma. The RPx platform enables injection into both superficial and deep lesions to address tumor heterogeneity that can contribute to checkpoint inhibitor resistance.

Product and service3 records
1RP1 (vusolimogene oderparepvec)
CategoryOncolytic Immunotherapy
Description

An investigational engineered HSV-1-based oncolytic immunotherapy designed to kill tumor cells locally and activate a systemic anti-tumor immune response, intended for use in combination with nivolumab in patients with advanced melanoma and non-melanoma skin cancers.

2RP2
CategoryOncolytic Immunotherapy
Description

An investigational engineered HSV-based oncolytic immunotherapy enhanced with anti-CTLA-4 expression to boost tumor killing and immune activation, being studied for metastatic uveal melanoma and hepatocellular carcinoma in combination with checkpoint inhibitors.

3RPx Platform
CategoryBiologics Platform Technology
Description

Proprietary next-generation HSV-1-based oncolytic immunotherapy platform with a dual mechanism of action combining direct tumor cell lysis with systemic immune activation; enables injection into both superficial and deep/visceral tumors to address tumor heterogeneity contributing to checkpoint inhibitor resistance.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1Bristol Myers Squibb (BMS)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical trial collaboration and supply agreement for nivolumab (Opdivo) used in combination with RP1 in IGNYTE trial. Replimune retains full commercial rights to RP1. BMS supplies nivolumab while Replimune leads development and commercialization.

replimune.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical trial collaboration and supply agreement for atezolizumab and bevacizumab for use in RP2-003 trial for hepatocellular carcinoma. Replimune retains full rights to RP2.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Vyriad is a clinical-stage company developing engineered oncolytic vesicular stomatitis virus (VSV) and measles virus platforms. Comparable as a developer of oncolytic virus immunotherapies targeting solid tumors with systemic immune activation.

TypeDirect peer
Description

Iovance developed and commercialized lifileucel (Amtagvi), the first FDA-approved TIL cell therapy for advanced melanoma. Comparable because it competes in the same post-PD-1 refractory melanoma setting that Replimune is targeting with RP1 + nivolumab.

3Oncorus
TypeDirect peer
Description

Oncorus is a clinical-stage biotech developing intravenously administered oncolytic herpes virus immunotherapies for solid tumors. Comparable as a direct competitor using HSV-based oncolytic platforms aimed at systemic anti-tumor immune activation.

TypeEmerging player
Description

DNAtrix is developing oncolytic adenovirus DNX-2401 (tasadenoturev) for glioblastoma and other solid tumors. Comparable as a clinical-stage peer using oncolytic virus approaches to drive tumor-selective killing and immune activation.

TypeEmerging player
Description

Genelux is developing Olvi-Vec and other oncolytic vaccinia virus immunotherapies for solid tumors including ovarian cancer and lung cancer. Comparable as a clinical-stage peer building an oncolytic virus platform with systemic immune activation.

6Turnstone Biologics
TypeEmerging player
Description

Turnstone Biologics develops oncolytic virus-based immunotherapies combined with tumor-infiltrating lymphocytes. Comparable as an emerging oncolytic immunotherapy peer focused on combining viral tumor killing with immune activation in solid tumors.

7Targovax
TypeRegional player
Description

Targovax is a Scandinavian clinical-stage company developing oncolytic virus immunotherapies (ONCOS-102) for mesothelioma and other solid tumors. Comparable as an oncolytic virus immunotherapy peer, though operating primarily in European clinical development.

TypeBroad incumbent
Description

Amgen commercializes Imlygic (talimogene laherparepvec/T-VEC), the only FDA-approved oncolytic immunotherapy, and is a direct predecessor to Replimune via BioVex. Comparable because both target solid tumors with engineered herpes virus-based oncolytic platforms, though Amgen operates as a broad biopharma incumbent.

9Cold Genesys
TypeEmerging player
Description

Cold Genesys develops oncolytic adenovirus-based immunotherapies including CG0070 for bladder cancer. Comparable as a clinical-stage peer focused on engineered oncolytic virus immunotherapies for solid tumors.

TypeEmerging player
Description

Lokon Pharma develops LOAd700-series oncolytic adenoviruses armed with immunostimulatory transgenes. Comparable as a small clinical-stage peer building an armed oncolytic virus platform with mechanisms analogous to Replimune's RPx backbone.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks2 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Replimune Group

Oncology Biologicsreplimune.com

Replimune Group is a clinical-stage biotech developing engineered HSV-1 oncolytic immunotherapies (RP1, RP2, RPx platform) for advanced melanoma and other solid tumors, with lead candidate RP1 currently under FDA BLA review (PDUFA April 10, 2026).

What Replimune Group does

Replimune Group Inc. is a clinical-stage biotechnology company founded in 2015 and headquartered in Woburn, Massachusetts. The company develops a portfolio of oncolytic immunotherapies built on its proprietary RPx platform, which uses engineered herpes simplex virus type 1 (HSV-1) — incorporating transgenes such as GM-CSF, GALV-GP R-, and (for RP2) anti-CTLA-4 — to directly lyse tumor cells while inducing a systemic anti-tumor immune response capable of addressing heterogeneity that contributes to checkpoint inhibitor resistance. Its lead candidate, RP1 (vusolimogene oderparepvec), is being evaluated in combination with Bristol Myers Squibb's nivolumab for advanced melanoma; RP2 is in development for metastatic uveal melanoma and hepatocellular carcinoma (the latter in combination with Roche's atezolizumab/bevacizumab). Replimune retains full commercial rights to both assets.

The company operates an integrated model that includes a 63,000-square-foot GMP viral immunotherapy manufacturing facility in Framingham, Massachusetts, and a UK subsidiary (Replimune Ltd.) in Milton Park, Abingdon. Replimune is publicly traded on NASDAQ under the ticker REPL and has financed operations through venture rounds ($30M Series A in 2015, $55M Series B in 2017), later-stage private and public equity (~$655M across 2019-2024 including a $225M public offering in December 2022 and a $100M PIPE in June 2024), and a $200M structured debt facility from Hercules Capital (October 2022). Its intended revenue model is direct sales to oncology centers and specialty pharmacy distribution for RP1 and follow-on products, contingent on regulatory approval.

The commercial pathway has been materially disrupted: the FDA issued two Complete Response Letters rejecting RP1 in advanced melanoma, the second of which triggered a 60% workforce reduction in April 2026 and a signaled potential scale-back of U.S. manufacturing. As of December 31, 2025, Replimune held $269.1M in cash (approximately $325M pro forma following a January 2026 ATM raise and additional Hercules draw), and the FDA accepted the BLA resubmission with a PDUFA target action date of April 10, 2026 — the single most important catalyst for the company's forward trajectory.

Replimune Group firmographics

Firmographics
Name
Replimune Group
Legal name
Replimune Group Inc.
Website
https://replimune.com
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
251–500 employees
Short description
Replimune Group is a clinical-stage biotech developing engineered HSV-1 oncolytic immunotherapies (RP1, RP2, RPx platform) for advanced melanoma and other solid tumors, with lead candidate RP1 currently under FDA BLA review (PDUFA April 10, 2026).
Ownership category
akta.pro rank

Replimune Group industry classification

Industry
Product category
Oncology Biologics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAACAF
Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Oncolytic immunotherapy
  • Cancer immunotherapy
  • HSV-1 biologic platform
  • Solid tumor treatment
  • Checkpoint inhibitor combination

Where Replimune Group is headquartered

Location

Headquarters

HQ city
Woburn
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Replimune Group business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical/Biologic Product Sales: Pre-commercial stage company with no approved products. Expected to generate revenue from sales of RP1 and other oncolytic immunotherapy candidates pending FDA approval. Clinical-stage biotech developing oncolytic immunotherapies for solid tumors.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Replimune Group product offering

Product offering

Core offering

Replimune is a clinical-stage biotechnology company developing a portfolio of investigational oncolytic immunotherapies built on its proprietary RPx platform, an engineered herpes simplex virus type 1 (HSV-1)-based technology designed to directly destroy tumor cells and activate a systemic anti-tumor immune response. Its lead candidates, RP1 (vusolimogene oderparepvec) and RP2, are being evaluated in combination with checkpoint inhibitors (nivolumab, atezolizumab, bevacizumab) for advanced melanoma, non-melanoma skin cancers, metastatic uveal melanoma, and hepatocellular carcinoma.

Product overview

Replimune Group is a clinical-stage biotech company developing a portfolio of oncolytic immunotherapies built on its proprietary RPx platform. The company's core products include RP1 (vusolimogene oderparepvec) and RP2, both engineered herpes simplex virus type 1 (HSV-1)-based oncolytic immunotherapies designed to destroy tumors locally and ignite a systemic anti-tumor immune response. RP1 is being evaluated for advanced melanoma and non-melanoma skin cancers, while RP2 is being studied for metastatic uveal melanoma and hepatocellular carcinoma. The RPx platform enables injection into both superficial and deep lesions to address tumor heterogeneity that can contribute to checkpoint inhibitor resistance.

Differentiator

Problem solved

Functional benefit

Products and services

  • RP1 (vusolimogene oderparepvec) An investigational engineered HSV-1-based oncolytic immunotherapy designed to kill tumor cells locally and activate a systemic anti-tumor immune response, intended for use in combination with nivolumab in patients with advanced melanoma and non-melanoma skin cancers.
  • RP2 An investigational engineered HSV-based oncolytic immunotherapy enhanced with anti-CTLA-4 expression to boost tumor killing and immune activation, being studied for metastatic uveal melanoma and hepatocellular carcinoma in combination with checkpoint inhibitors.
  • RPx Platform Proprietary next-generation HSV-1-based oncolytic immunotherapy platform with a dual mechanism of action combining direct tumor cell lysis with systemic immune activation; enables injection into both superficial and deep/visceral tumors to address tumor heterogeneity contributing to checkpoint inhibitor resistance.

Quantifiable outcome

  • 33.6% objective response rate in advanced melanoma patients who failed anti-PD-1 therapy (IGNYTE trial)
  • +4 more outcomes

Companies that use Replimune Group

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Replimune Group technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Replimune Group partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Bristol Myers Squibb (BMS)coreStrategic or Co-development PartnerClinical trial collaboration and supply agreement for nivolumab (Opdivo) used in combination with RP1 in IGNYTE trial. Replimune retains full commercial rights to RP1. BMS supplies nivolumab while Replimune leads development and commercialization.
  • RochecoreStrategic or Co-development PartnerClinical trial collaboration and supply agreement for atezolizumab and bevacizumab for use in RP2-003 trial for hepatocellular carcinoma. Replimune retains full rights to RP2.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Replimune Group competitors and assessment

Company assessment

Emerging players

  • Vyriad: Vyriad is a clinical-stage company developing engineered oncolytic vesicular stomatitis virus (VSV) and measles virus platforms. Comparable as a developer of oncolytic virus immunotherapies targeting solid tumors with systemic immune activation.
  • DNAtrix: DNAtrix is developing oncolytic adenovirus DNX-2401 (tasadenoturev) for glioblastoma and other solid tumors. Comparable as a clinical-stage peer using oncolytic virus approaches to drive tumor-selective killing and immune activation.
  • Genelux Corporation: Genelux is developing Olvi-Vec and other oncolytic vaccinia virus immunotherapies for solid tumors including ovarian cancer and lung cancer. Comparable as a clinical-stage peer building an oncolytic virus platform with systemic immune activation.
  • Turnstone Biologics: Turnstone Biologics develops oncolytic virus-based immunotherapies combined with tumor-infiltrating lymphocytes. Comparable as an emerging oncolytic immunotherapy peer focused on combining viral tumor killing with immune activation in solid tumors.
  • Cold Genesys: Cold Genesys develops oncolytic adenovirus-based immunotherapies including CG0070 for bladder cancer. Comparable as a clinical-stage peer focused on engineered oncolytic virus immunotherapies for solid tumors.
  • Lokon Pharma: Lokon Pharma develops LOAd700-series oncolytic adenoviruses armed with immunostimulatory transgenes. Comparable as a small clinical-stage peer building an armed oncolytic virus platform with mechanisms analogous to Replimune's RPx backbone.

Direct peers

  • Iovance Biotherapeutics: Iovance developed and commercialized lifileucel (Amtagvi), the first FDA-approved TIL cell therapy for advanced melanoma. Comparable because it competes in the same post-PD-1 refractory melanoma setting that Replimune is targeting with RP1 + nivolumab.
  • Oncorus: Oncorus is a clinical-stage biotech developing intravenously administered oncolytic herpes virus immunotherapies for solid tumors. Comparable as a direct competitor using HSV-based oncolytic platforms aimed at systemic anti-tumor immune activation.

Regional players

  • Targovax: Targovax is a Scandinavian clinical-stage company developing oncolytic virus immunotherapies (ONCOS-102) for mesothelioma and other solid tumors. Comparable as an oncolytic virus immunotherapy peer, though operating primarily in European clinical development.

Broad incumbents

  • Amgen: Amgen commercializes Imlygic (talimogene laherparepvec/T-VEC), the only FDA-approved oncolytic immunotherapy, and is a direct predecessor to Replimune via BioVex. Comparable because both target solid tumors with engineered herpes virus-based oncolytic platforms, though Amgen operates as a broad biopharma incumbent.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks2 records

Key highlights7 records

Customer concentration

Replimune Group social profiles

Digital presence

Replimune Group financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Replimune Group leadership team

Management profile

Number of profiles

Profiles11 records

Replimune Group subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Replimune Group funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Replimune Group M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Replimune Group

What does Replimune Group do?

Replimune is a clinical-stage biotechnology company developing a portfolio of investigational oncolytic immunotherapies built on its proprietary RPx platform, an engineered herpes simplex virus type 1 (HSV-1)-based technology designed to directly destroy tumor cells and activate a systemic anti-tumor immune response. Its lead candidates, RP1 (vusolimogene oderparepvec) and RP2, are being evaluated in combination with checkpoint inhibitors (nivolumab, atezolizumab, bevacizumab) for advanced melanoma, non-melanoma skin cancers, metastatic uveal melanoma, and hepatocellular carcinoma.

Is Replimune Group a public or private company?

Replimune Group is a public company. It is classified as public and is currently operating.

When was Replimune Group founded?

Replimune Group was founded in 2015. It employs 251 to 500 people.

Where is Replimune Group based?

Replimune Group is headquartered in Woburn, United States, in the North America region.

How does Replimune Group make money?

One revenue line is on record: pharmaceutical/Biologic Product Sales.

Who are Replimune Group's main competitors?

Emerging players on record are Vyriad, DNAtrix, Genelux Corporation, Turnstone Biologics, Cold Genesys and Lokon Pharma. Direct peers are Iovance Biotherapeutics and Oncorus. Targovax is listed as a regional player. Amgen is listed as a broad incumbent.

Does Replimune Group have an API?

No public API is recorded for Replimune Group.

What industry is Replimune Group in?

Replimune Group's product category is Oncology Biologics. Its primary akta.pro industry code is HLAAACAF, Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Quiver QuantitativeReplimune Group Stock Short Interest Rises to 36.13% | REPL Stock NewsReplimune Group short interest rose to 36.13% of the float on October 30th, totaling 24.61 million shares, up 6.23% from October 15th. Insiders have made 14 sales and no purchases in the past six months, while hedge fund activity shows mixed moves.Simply Wall StWhat Just Happened With Replimune Group (REPL)?Replimune Group reported Q2 net loss of $57.12 million, down from $83.1 million a year earlier, and H1 loss of $126.89 million from $169.79 million. The stock gained 51.09% over 30 days and 66% over 90 days, while a fair-value model values it at $19.50, implying overvaluation.YahooHow Investors May Respond To Replimune Group (REPL) Narrower Quarterly LossReplimune Group reported Q2 2026 net loss of $57.12 million and six-month loss of $126.89 million, both lower than prior year. The narrower losses suggest tighter cost control as the company shifts toward commercializing its oncolytic immunotherapy portfolio. Commercial uptake of TUDRIQEV remains the key near-term swing factor.Simply Wall StNarrower Losses Could Be A Turning Point For Replimune Group Stock (REPL)Replimune Group reported Q2 2026 net loss of $57.12 million and six-month loss of $126.89 million, narrower than prior periods. The company projects revenue of $296.9 million and earnings of $47.4 million by 2029, with a 6% downside risk noted.MarketBeatReplimune Group (NASDAQ:REPL) Stock Rating Upgraded by Wall Street ZenWall Street Zen upgraded Replimune Group from sell to hold, while other analysts raised ratings or price targets. The stock opened at $17.61, and insiders sold shares to cover tax obligations. Analysts expect a -2.74 EPS for the current year.American Banking and Market NewsReplimune Group (NASDAQ:REPL) Stock Price Expected to Rise, Leerink Partners Analyst SaysLeerink Partners raised its Replimune Group target price to $31 from $19, citing an outperform rating. The stock opened at $17.61, with other analysts also adjusting ratings. The company reported a loss of $0.54 per share, beating estimates.American Banking and Market NewsReplimune Group (NASDAQ:REPL) Stock Lifted to Hold by Wall Street ZenWall Street Zen upgraded Replimune Group from sell to hold, while other analysts issued mixed ratings. The stock opened at $17.61, and insiders sold 79,124 shares over three months. Analysts forecast a -2.74 EPS for the current year.MarketBeatLeerink Partners Forecasts Strong Price Appreciation for Replimune Group (NASDAQ:REPL) StockLeerink Partners raised its price target on Replimune Group to $31 from $19, citing an outperform rating. The company reported a Q2 loss of $0.54 per share, beating the $0.78 consensus, and insiders sold 79,124 shares in the last quarter. Analysts forecast a fiscal-year loss of $2.82 per share.TradingViewLeerink Partners maintains Replimune Group at Outperform, raises price target to $31 from $19Leerink Partners maintained Replimune Group at Outperform and raised its price target to $31 from $19, a 63.2% increase. The target implies 93.0% upside from the Oct 28 close of $16.06.The Motley FoolReplimune: 3 Key Takeaways for Long-Term InvestorsReplimune launched TUDRIQEV for advanced melanoma on Oct. 28, 2026, with over 15 centers prescribing within 20 days. The company holds $307.8M in cash and expects to fund operations for over 12 months. It plans to file for a J-code by April 2027.